Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 6;11(8):3916–3931. doi: 10.7150/thno.52496

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Pharmacokinetics and targeting ability of P-EVs towards injured endothelium in vivo. (A) Pharmacokinetics curve of P-EVs. Data are shown as mean ± SEM (n = 4). (B) Ex vivo optical imaging of the infarcted hearts at 24 h after intravenous injection with PBS, DiD-labeled EVs or P-EVs. (C) Semi-quantification of radiant efficiency of hearts in EVs and P-EVs group. Data are shown as mean ± SEM (n = 6, *** P < 0.001). (D) Ex vivo optical imaging of the crossing sections of hearts from base to apex in P-EVs group. (E) Ex vivo optical imaging of other major organs at 24 h after intravenous injection. (F) Semi-quantification of radiant efficiency of the organs in EVs and P-EVs group. Data are shown as mean ± SEM (n = 6). (G) Representative fluorescent microscopic images of DiD-labeled EVs or P-EVs colocalization with CD31 in the infarcted area (red: DiD-labeled EVs or P-EVs, green: CD31, blue: nuclei).